NVTA - Earnings call transcript Q4 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. My name is Emma and I will be your conference operator today. At this time, I would like to welcome everyone to the Invitae Fourth Quarter 2021 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. you. Thank Instructions] [Operator Relations, begin Investor conference. you Finks, your may Jack

Jack Finks

call. Thank good joining quarter Thank results and everyone. and you year fourth you, operator, XXXX afternoon, for our us full for

Roxi Joining Wen, us Sean today George, CFO; Ken Knight, are and COO. CEO;

that from therefore, business Factors most additional We titled on statements services, forward-looking you of section results things, date in information as Reform to restructurings, and the acquire, Risk future their remind financial materially services, actual could services like product timing, Securities we demand for among this additional cause the assume, don't infrastructure constitute plans businesses our of Act. prospects, our settlements. hereof. demand that legal materially in or stated of investments, harbor and our manage meaning are statements accurately particular, operating and safe begin, predict that other current refer we on It's the various investments including historical, our Private market Litigation on XX-Q, recent that of plans expectations. forward-looking conclude our These actual focus to provisions results results, our we to product remarks opportunities, the you factors business to differ could difficult our the pipeline statements company operations. performance Before These for for and those our and call not I'd and any within from our and that acquisitions, outlook. speak make to differ about future integrate reimbursement strategy, only we Statements future and of

at net cash as cash and well and ir.invitae.com. cash share, encourage to in per available you appendix to slide We company's the including our expense, from general expense and the With deck, of measures development, in GAAP press debt, financings the and exclude the non-GAAP gross revenue, of can reconciliations, visiting received from loss and call website selling as review and income of and of exercises research securities, burn I’ll items, cost GAAP, commentary and in the our the which and available, applicable, accepted as the cash the prepared call, We accounting non-GAAP expense in quarter. to supplement acquired the and exclude equity United to you principles our intangible several consolidated or assets, liabilities, includes including results, combinations, from the operating consideration as to our monitor accordance To metrics, related key non-GAAP of other We fair connection press stock-based grants and and acceleration benefits. or post-combination measures. certain listen value in as generally acquisition-related we consider to acquisition-related and business with today's the adjustments company's of financial applicable, we statements contingent encourage you net, may operating section from equity received amortization States, both of earnings are other among profit, well as payments you income bonus with financial As assets our on release net growth Non-GAAP which acquisition-related which burn. conference over have marketable changes to results tax the of compensation, access in Investors administrative, turn release include that, by non-GAAP marketing warrants. Sean. loss

Sean George

and afternoon, Jack, everyone. good Thank you,

today, outlined something Invitae. call we're see in unique our you'll As at into tapping

numbers for forward immense line we to in personal call to ahead, of will top demand sometimes Today's meet annual unmet Aside execution fundamentals as revenue the and short-term growth positioned our everyday be from we well health. genetic solid continue the metrics quarterly that are years back heavy. and in and use even information fluctuations, the hurdle

our into respectively. approximately with year deep throughout volume XX% finished strong full We in and to XX% very growth growing the So expected, performance, million a patients of life. account stages I platform at revenue all our provider but of financial were go and addition and the almost year as summary won't growth

health can to now health continue the markets are that point a of services in personal immense we develop just set better arrive growth genetically to will durable and like coming presently As picking presented out very integrated ability infrastructure large. I our chronic immense this for high What and dominate medicine at an large, from the understanding of landscape, sounded project this with from can shape transforming impact opportunity. sustained is genomics value a result about human payers industry healthcare the the make meeting, converging own and this of and and attitudes most require off is To and years they systems be history. for of the paying future role The and and the every genome kicked engagement a improvement guidance the even diseases national investment condition to information, off. to greatest the context solutions healthcare mentioned recent outcomes, look driving information of healthcare specialties driving support the industry. managed provision general single clinical relevant we're converging across committed plus to that maintaining for is minimized or provide healthcare. all where and following back the adopt risk this dawn if digital At shift unlocking or throughout cycle genomic single their targeted health and in fundamental the linking if private markets of studies will customers, its company information is years become better coming mean genomic The expanding replaced well that customer's genomics fiction. in medical I capabilities by tailwinds will and growth shift solution company information multi-omic of have data the own a The understanding but major that test impact a being areas is full certain and therapies, for up, genome be the their to provide less the journey the science concept changing lead the cost in time by life. that is of era. be technology of health at soon perceptions time, to pipelines, will medicine the personal medicine. reality genetic the or of science, those and genetics will far of to given individual's at of call can rendered of medicine, customers expand. subset focus patient it. continues in virtually care for can when for the rapidly providers, a a and step could to The decisions medical deliver of the understood underpinning a in knowledge you take The our rates the within saved shift and decades And be human will broader a and journey. in A In in that outcomes to by any XXXX, XX biopharma quickly number be or But

commercial growth as following. improving over neurodevelopmental customer's specific to a launched, set broad offering next large mom need offering In three in pediatric children, stage logistics, and This we two still combined genomic continue ordering, our for based decision the the we of incoming moving As see disease, great genome. partners improved our in the throughout backdrop for disease testing, health to with In coming delay growth improvements baby. and reproductive interest years, both core young recently in women offerings, to and at this reimbursement an health, this rapidly improvements unmet of in our of growing will drivers services support for offering year clinical life. exome biopharma from genetic have patient see and on growth we having a ease for drive

will than companies cancer. the This our to growing attractive offering, more monitoring and a offering is for of This our year, or leading reimbursement oncology, we beat combined any armed with selection be For inherited in in demand us information helping therapy risk that precision and leading market. good comprehensive the as cancer cancer solutions position with better well solid and for up the commercialize oncology demand adding the oncology fight for set distributed to customers risk and for understand disease. their

of sharing growth are across our patients interested own content, with growth building But capabilities technology our on forward revenue part ecosystem of in day in investments data in outsized we contributor fuels and during platform patient business today, financials. in our all life as the months. much we're I out All about for and broken their few this utilizing look grows large business. We've our of digital we'll our an more production, expect a partners. the a network network this to recently data and stages services interest these who be in line health focus to tools to of data

going that quarterly the for but the indicators of for some investors our undertaken This be and our non-traditional be burn. We'll everybody performance a quarter-by-quarter. also two invite shift not big time, key company just primarily company annual to the to these reasonably For line metrics on and for is we to gross to indicators top also business, And and basis. These are of cash the again. guiding first key we're to we'll next level introducing reasons. performance margin follow run watch a

a we're ambitious strategy, it's pursuing a and First, building an undertaking. new category, business novel

forward. specialty the not tools the such, or used measurement business going are standard this helpful industry in measuring diagnostic in modeling As

execution as attempting detailed about are help understand the we investors We thinking and running as follow be our a to thinking useful at all are and transparent how level. to business is

we've large growth to results through we'll size and company at be the is it. the many strategy aggressively unique model, two, billion burn will at pushing operating future. and this years targets toward I'll before of in Roxi know point and of growth cash for margin flows numbers a our hand industry generating unique such this X.X year's all providing and the at past Second, for metrics. reduction, this now the billion cash sustainable to The adding picture we costs, pursuing pursuing clocked us X our walk then and forward-looking be call instead clear March revenue in of gross that leading

Roxi Wen

for joining Thanks, Sean. all And you us thank today.

the For the discuss cash including burn. call, we'll of remainder numbers, non-GAAP

to noted also to we the included review press As our set to quarters, and the billable to it by providing data. and of of the is allow urge of non-GAAP reconciliation for business included prior unit investors release metrics two slide non-GAAP volumes, understand comparison back financials easier We ASP, in deck. financials QX the per section, detailed at the In cost in and appendix numbers.

this I Before we move our that last detailed the provide to and cost update, we want the in per the time metrics will be blended unit update. financial ASP quarterly note

other performance data the stages In patient selection other in million million evolves therapy million approximately as million. biopharm $XX approximately nicely the health from quarterly continuing the generated was growth, including companion identification various As part all deck. cost price four appendix across of XX-K revenue past and $XX to cardio, all offerings, QX three basis our We fourth follows: from Revenue and with breakdown $XXX revenue $XXX years. Data our the and filings. our less NIPS, of XX-Q $XX products and be the data model dozens will our include covering was revenue million from on and This analytics, in performance. neuro, of in maturity, from revenue diagnostics, the of selected approximately XXXX, dashboard, categories, become increased financial we'll helpful oncology, data aggregate our slide includes billable business and and Consequently, certain metabolic Data-as-a-Service reproductive quarter testing other women's disclose properly on a to and rare while new and approximately as areas management, each metrics programs. and breakdown volume and of testing, data and focusing assess comments carrier, screening. newborn and and disease tests, germline including platform across we

Moving down the P&L.

acquired the margin non-GAAP of gross revenue non-GAAP year. to expenses X% of the $XXX QX businesses. In Non-GAAP compared million, was XXX.X% XXXX, which profit newly or margin of operating expenses operating include to XXX.X% revenue to over in margin or translate $XXX XX.X%, non-GAAP a growth improved the quarter, from fourth gross prior XX.X%. $XXX gross For from prior slightly XX.X% year. decline million was the The costs of million

earlier in the come level. growth and goal As rate We're of will we manage we business as to returns down in the spending total this and XXXX. scale on committed portfolio at stated on calls, investment the

equivalents, XXXX. excluding Full and burn Moving is XXXX was marketable to totaled at acquisitions our or compared model for and cash including billion $X.XX position, $X.XX to restricted September cash, and XX, billion Invitae’s cash December securities business year million million, cash $XXX highly expenses. at $XXX differentiated cash cash XXXX related XX, ambitious. acquisitions

As discussed the offer on steps the last fundamentals business. spent work of the and months conference we visibility the eight the into past taking help our necessary call, to doing

and our on population clinics, not based of These vitality Growth business systems, but commercial sharing, their product or the selected our through set Going revenue of operational systems Testing forward, new new we’ll decisions is and strategic current pharmaceutical on portfolio. over to developed investment of years describe of investment. metrics freshness least data category ability And for last product the returns a our visibility or of for acquired key hospital last developed leverage. patients to to include new three and points connects for provide the our categories patient these patients clear available significance demonstrates expansion Services with metrics access the and accurately partners.

rapid the a show growth, a performance with cash cash to operating Today, and with by at operating OpEx the we revenue that In flow we standard cash self-funding due continued addition of with cash capital a will our percent improvement. flow operating metric, consistent report our is scale. as is replace scale form now of so can reaching focus current the investment net model to

be need not to attention quarter useful metric. by category progress, will a success to but every detail about and every signal even we on trade-offs into do will not from in measured every every be time metrics dashboard, that these go increasing To So also they call plan and areas time.

these work in balance consistent we into a move is And through a as and sharing objective provide perspective growth, of their share a also we available the portfolio the and performance. forward. update our few Our more on to of highlights who over Similarly, partners, are I of transparency patients three and serve nicely. these offer accounts active fast last and number business, here. dynamic rapidly increased changing Vendor to will years. quarterly intend maintain metrics a extended We number them publish both have active to as the to data

in has by data, non-patient primarily member and vitality XX% from XXXX Revenue growth steady average $XXX by measured patients including New of period $XXX product grew per XXXX, platform in seen tests specific revenue, by from and XXXX XX% ordering in to driven number the of total in for patient of the to divided the in the per XXXX. growth patient kits. platform expansion oncology services revenue

proof heavily growth potential by the of have we from point invested platform patients diverge since encouraged the revenue inception. ASP, from early this per starts we’re As to future

operational considerable pressure margins to our of gross compared experienced downward Non-GAAP excellence. to XX%. have target as long-term Moving

label. of already variable seen levers in and costs margin We in in improve multiple of the drive XXXX margins in was efficiency productivity impacted XXXX productivity. actions around the that in Examples from XXXX the as material, gains. in costs productivity. note some and the have extension taking in driving and performance to a and to margin when Gross And period. and variable improvement lab the growth is business more of than XXXX, XXXX. important three can measures offset expect cost shipping volume lower include COVID Variable relative over those recovery in to we’re growth margin significantly this bounced members held volume decline products, represent productivity metric negative that last favorable back a we’ve years The it

growth new both reflects and for investment capital of is of stock the a top impact demonstrated the use front, ambition. and our our percent metrics. and bold in product strategy strategic M&A, growth On as line trend including revenue and And investment the this vitality investment of R&D partially cash

or our million to guidance $XXX the providing year, guidance we’re XXXX. As revenue approximately XX% for of growth for

and goals upside Sean strategic fast share activity. we internal represent high capture market for organic growing gives believe As for levels growth accessible will of our see mentioned, the activity dynamic at market But target and we always some keep for the and inorganic combination XX% room for both opportunity growth industry leading us years. the and

XX% margin, to in increase of end growth in year And be gross run gross expect exiting the we throughout this than our margin a guidance future XX%. For and rate guidance range the over And for of year to this XX% cash years. at and course the targets. metric may year. a higher operational we steady the burn margin full rate choose revenue year run discontinue our should This finally, showcase to improvements XXXX,

a targeting million that burn that burn to related include cash note is XXXX. and $XXX a acquisitions is during cash of XXXX. than cash for important any million million burn the $XXX in from $XXX of million this it deploy and It reduction $XXX between We’re cash activities, target more we

a cash in the We we enables positive also business ongoing cash continue to plan rate exit driving reduction burn XXXX that as run the to with future. flows

over call Ken? Now programs. I tie and results Ken with some some together factors operating would metrics of who to turn the will core these

Ken Knight

from grow Thanks, burden core was not Roxi. cash to to aggressively. us that a a distracts our flow pathway Building objectives positive operating

revenue and of combined cash In capital industry-leading in will margins delivered replace the pleased from period, that XXXX XXXX fact, deteriorated climb global nice We flow trajectory our for ongoing the it line. some markets saw a pandemic. teams our providing cost fuel of largely sales products our growth. jet the as same expand the that talented is with operating gross to to we top breadth But with positive investments were during with our

unfavorable result high required as our by access of to easy. safe. and unprecedented and demand in agility while a patients. we We people And patients inefficiencies demand focused was that supply and And were experiences. and not experienced also on pricing protect and remain our uneven variations through We customers servicing keeping nimble worked it was constrained that patient customer drove to

acquisitions a our ArcherDX integration strategic and kept deep also Genosity, the we product and which got into expanding and However, eye long-term, are an other Medneon, unquestionable on offerings. have of health our breadth see made of Ciitizen to our we developed the path of to We margins digital actions platform leveraging customers gross to list to and improve in XXXX. deliver a value robust

of key significantly list with delivery. are past a establish more we over critical taking a years, increased with Recognizing spending. acquisitions generation must spending M&A. of for against developed leaders teams, This several these reducing for assigned resource our we imperatives approach to revenue which did of value of All not exercise, initial applied. accountable a we’re our non-negotiable has ever OpEx to have as the who more resources earlier, and that visibility reallocation I be imperatives. than mentioned into several that percentage now priorities led the an To align

for cash quality but the inspecting looking through of there as We we lens improving pricing revenue revenue our the And opportunities, flow specifically grow. execution, inspect finally, way also work our reimbursement, to and for not is are on implications. product positioning operating only growth,

how reimbursement task have gauge in plan So gross in We enhancement pricing product from assets. exiting move we of let’s at of place The of XX benefiting opportunities, hand at and at framework to XX% modernization, exit and Slide and this margins, margins. list move XX% XXXX driven automation mechanisms from the recognize the integration to operating of exiting productivity, XXXX acquired chain covers our look improvements gross significance the continuously progress. to recently to supply and

OpEx As XXXX significant curve we XX% to growth expense XX% in Slide shift XX growth in approximately a growth see the to OpEx, in from in XXXX. in you’ll reduction

seen revenue for product with alignment differentiated While by at overall XXXX development year, year. unlocking The are maturing the and by trade-offs. this imperatives, the cost or I’ll this drive But leading planned there acquisitions to have business the cost line the now industry top an or floor you future pass ability the Sean will by and key closing. to our gross margin we will still was of for be And experience the in back investment the influenced necessity while an be XXXX customer as to growing slide, related cost fundamentals. improvement launches pace, earned yes, deliver committed to earlier so Thanks. for for to patient

Sean George

Ken. our see We’ve we to shown ramp long future pulling you, how the business model to Thank an medicine. of effort view this in forward describe

And extend a thank for on a most not When nobody time day-to-day the in ago, and get more health and information involved genomic almost the personal our for benefiting to in the on essentially of time. system network other of our board and take with investors the our exciting support can who who the wellness. important years in our demonstrate the story. years them. throughout information we up where of platform progress we started combined environment addressing data Current other have patients market in I was patients this needs that the notwithstanding, on hearty across can be XX health the our era, network. their bring healthcare employees partners this and company and The in genetic information been we’re genomic medicine shared from into network and a from correctly patients to with most curve Our anyone we is information work more add industry can that our therapies invitation and emergence genetic a do behalf, progress years their to future the the and we more XX for will. be transition exciting diagnose the doing. more more faster. lifespan global the to everyone especially of little and services patients us It’s provide, now, we can scale part and market their over to earlier can I want

go thousands we being of say teammates With that to lives our isn’t people’s lives. out global geopolitics before me it’s to as the of X,XXX Q&A, the have partners as out today, at every important most in point and waking to thing small obvious thing Ukrainian will I played of is the do the a that, Ukrainian to Russian Now, this our compared Q&A. anything and call really really There while more business in company expense the Emma but back feel region need moment we to mission on for that, customers, well I’ll for the over to. be tending pass the

Operator

from Your Instructions] question today Cowen. Brennan comes [Operator first Dan with

line unmuted. is Your

Dan Brennan

Thank better you. and It’s I’m change. us of on give create is little huge of a of guess, our occurring first you than your kind kind is cuts pretty I is through XXXX kind step kind point growth? down, risk what kind which the Thanks And across you OpEx a since material in a far actually flavour guidance, how wondering what’s on the of just would items. kind segment SG&A the line and to that the pressure of those top a the in in Sean line walk – burn this R&D, your Great. maybe of kind we have be guys. impressive question if Can model. just growth what of

Sean George

revenue, closest I balance. to to the tending like – top, just of let a it’s just be pay $X pushing the are Sure. sense. attention is I I then make – to majority enough But of mistake. would I’ll admit, ton to numbers big and answer billion Ken that we’re middle I’ll a bottom getting past the and both billion Actually top getting no the It’s makes the going mentioned, of it. and $X

the out makes growth this scale just the would foreseeable to opportunity it’s unlimited time growth more the with chase But this has we of sense. capital, future. far There’s plan there continue industry current Our leading it. company for for

to I and commentary he think Ken color each that. really speak it’s though, of important can hear from item kind line to give on

Ken Knight

improve first Sean. margins. our we is have as think actions I on underestimate have gross thanks, margins. very that long margins. impact would strong first are improving going What And don’t Well, to That’s, gross robust to all, we the of of that a I we’ve is and say gross foremost focus list described of the and

burn. to early that’s resources. our One OpEx to is us on cash couple our did improve some a work So we an align reallocate standpoint, From the things. going to do allowed obviously to to imperatives

So as much items priority driving reallocated because higher to we top to not the did have resources are the some grow we line. that

really actually between we’re to it’s resource really grow So it that down our and then a our year, track with to products feel great launching good ability have top match those sure boils have the marketplace. the this line we because and have development the on making we line And top sure into we secondly, to priorities. driving we making new activities the aligned interests sources that of deliverables that stay coming out are new about

growth. costs, And our suppressing are with so controlling also we not summarily, but

can feel about both we think the I we and good so and will do it’s situation do both. both And doing we where

Dan Brennan

line. then And kind it. maybe the of follow-up a Got on top

So anticipating. of driver business within going give XX% not on us Sean, give to of likely material that why some the the oncology rate? you’re was and you it’s you just question. in of be Can growth Archer kind a Archer second around break the sense those? us Could my where an the us XXXX? growth kind growth out franchise And Street on in color oncology impact about thinking would products to about update be should think we your of and of the I any give how guess way timeline that kind and

Sean George

oncology. Yes. And business. of think relevant to rest also the the it’s I It’s relevant to

and which break top to contributing product our out, this you’re up growth, disease you last new fueled M&A. putting three years first by line the if included. in is in products which we’re new starting oncology vitality take whatever back, the step is So of outsized a why in are kind acquired The are

testing core our Our product impressive, very to put leading inherited growth – strong core a franchise growth, very growth numbers. continues

have monitoring. local demand will or of IVD And include solutions launching kind it’s the oncology and group’s And for not service, even year, to we backdrop break recently increased in that out, is the leading year industry the selection, of launched five the to decision with at start six the products been call And of cancer second oncology for top therapy just oncology especially kits distinct So we really we’re in best precision at think all Japanese we geographies. personalized around of revenue regulatory The in that call perspective. play. we the the in growth. of least for growth. it oncology of foundation which There’s oncology, other contributing the when way an we’ll the therapy some just half add drive which in do exome-based growth. load half to line the this is at look points key you a approvals globe, in different look is, our first on And growth to addition globally, monitoring that, from selection it already

going product product continue foundational will technology out. will is which those tell and on every versus of contributors All of that’s offering be quarter a to new and here And that, break out products kind story. to

offering what going there’s we’ve obviously, with commercial But It’s I XX, think important to medical four chart claim oncology lay companies market. screening as need about later to precision brand presence, think they for really our got We’re little monitoring. I recently, – the to to most. really There’s and and a very do oncology precision strong an time in very the about saw really, opportunity. like – an exciting chances genetics, we’re therapy be table a more some excited selection, something everybody’s is a strong given than I excited

Dan Brennan

And data... insisting I’m more, I one know

Roxi Wen

bye. Good

Dan Brennan

Okay. Thank you.

Operator

Your next SVB from Wiatrowski Chad line question comes with of Leerink. the

Your line open. now is

Chad Wiatrowski

for it How’s taking question. the Hi. going? Thanks

longer-term? market data what venues yourself up? in in MRD in with some sort related expect type such Just as highlight of can positioning PCM, of and how to of studies data to ongoing coming the can And you see XXXX the see ASCO we these you

Jack Finks

moment. line, a speaker Just right We back lost they’re a moment just now. in the dialing

Sean George

hear Can you me?

Operator

having currently are technical difficulties. We

placed time, patience. Difficulty] that you call will for until Thank you holding. on shortly Your Thank will your for your musical. lines resume be [Technical

the question with Chad will Leerink. Wiatrowski with resume SVB We from

Your line is open. now

Chad Wiatrowski

for the guys. question Thanks taking

we wondering longer type I with be horizon. view these to was here how important And can market times? see upcoming sets some how you with that will of conferences longer-term? in of you And if terms perspective follow data in capturing up in XXXX data what share expect Just of PCM, on the highlight large sort can

Sean George

Yes.

the on end XXXX performance year of think studies of or eight going of throughout test. – of coming of graph in and the handful XXXX So than can toward I of that we’ve a – intercept the info pack don’t I out but of throughout me, the everybody, on got worthy note. actually end send of there’ll can front be the between blood the have out work we that of Later them we XXXX to kind – are seven consortium, going METexXX

at the show to up, molecular the detect dozen variants coming – earlier And think we’re is longer. or the molecular going you which The we large total treatment ability coming if to level at is, and be this And first demonstrate and kind I patients is else the reimbursement, I need back that hands in I the it and the all out of the enough number battling of for where, – that sum of thing know been perspective trials earlier cancer oncology applied The run for so. principles there. kind or prospective years again, mutations has every for as we to is specificity technologies our long good that trials is space this know than is live a sensitivity is and of for early entire be technology level and basic, from the adjust to the known and that indeed that variants to that those quantitative. people already data think of the bring comparing to treat is any generating the that guidelines basic what are of the targeted for as anybody in all the better targetable because doing – what new there research view or think well. in premise, resistant reason yes, cancers, pointing individual that

and so the struggle companies – in And preponderance the that of have be the that a data, for sensitivity data an market kind specificity capability demand the And for share. shows then run, of long your quantitative them. answer the to of amount will then these drive to question in of all utility of the engaged is tests amazing market going

Chad Wiatrowski

just In What light launches, other follow confidence to down burn product Thank guide helpful. you new clinical it. quick that ongoing that’s be able cash those the ramp and of you. And trials And high and of highlighted. gives to Thanks. end you very to some a PCM, commercialization a up That’s there. reduction?

Sean George

still increase with mean, margin on And the investment year’s up, you showing sales right has year XX% can total marketing efforts on a with will continue lot last sales chunk growth. specific specific it been last the a Yes. ton That is in marketing Ken and line. and It’s efforts a a and reduction top very and a example I gross of to this R&D a slide in opportunity to see then it leverage. There’s from XX% on leverage, covered good the large big the operating chase. of year space. of G&A

the burn where that balance really now we’re metering comfortable sheet, right we to and we feel are Just with we’ve the against that doing cash that got, end.

Chad Wiatrowski

again. Thanks,

Operator

Blair. Brian next the of comes William Weinstein from Your question with line

now open. is line Your

Unidentified Analyst

Griffin frame on can ultimately each I corporate Thanks This to just on and gross margins on going the gross the guide, the on questions. are But Brian. margins. good in higher where segments for from? just for appreciate operating four gross Hey first the margins guys, afternoon. come and you the the for margin level commentary corporate benefits is those of the Maybe business

Sean George

reason be fundamentally margin is Ken walked that this want don’t the a these area, I it honest, a To quite generating platform genetic overall, actuality because to path single through data the where but mean, think I gross it’s And to. is out. the Yes. there’s simple, platform. not that’s it to single break results. it’s we By to the we business get a rate in deliver effectively and exit

start then lab the out kind does factoring and reproductive of production really our one improvements parts tests kind going different a for the and of parts multiple different were you of kind said, of the that of include health a those category different generate of patient, losing little With results we where NIPS of PCM, business Some the wet of that we’re therapy bit for way The heritage gets putting MRD production the platform. trees. by per in mainline But gross when businesses. bit force in different mix is of and sign of And essentially non it for jumble. all all of you apply production areas. get the all the little in of part enough. and selection margin also place the then testing costs, than limbs kind when is of genetics, the that all a to the Obviously, all

it of and plenty the it’s of for out really we’re game But that way And area. essentially, the done the not blended major to a – something of we is the way really where So the where by pricing we ASP, to – break end year. that overall about gross confident years. levers in kind the and going the view consistent the by kind of is this business have no, long real past is we’re with saying over over we’ve and going or what’s GM of pull, over we’re trending And margin it year?

Unidentified Analyst

a talked entry other round company, Understood. the the there. do obviously what a you company. Ciitizen of But about to to you big ultimately diagnostics an and just you transition? transition need this a was from lab more Okay. then, areas out think bit information little step are And enable

Sean George

been and many No, consistent point appreciate actually, what question. years. is for kind Yes. of with would I this out been kind again, we’ve I consistent the company of pretty the very And we’ve strategy –

more utility than now individual really put a of a show been it’s public worth always think genome’s new changed seven We’ve from an our pretty death since or fundamentally in then. model cartoon of information a business years business. business has imagined category about not that. been for clear play testing birth much That always that is I this ramp we – eye. much is the of a ramp it’s more – to to We’ve information into pretty an little

much now commented two genetic information. the have this that in utilizing disciplines beyond dramatically going move decision comfort here into that’s tools three the patient’s clinicians with the and to see some There’s specialists oncology, way administrative into with in to better and really, just are of tools of still decision or by to What move interested way way the all kind do are in and we’ve the going in kind the to on is of noted, customer but community the you’ve digital all things ordering continued progression. in experience that And that are out support. care of digital that the information years As paediatrics the support are those the and and middle providing we’re next on information we managing really to clinical setting. themselves, ways more tie of going missing can their important. cardiology, that to improvement primary going and customer is where that governments just we’re behalf. clinical the it It’s very system even kind this clinician on be individual not out The side, maybe tools

that Ciitizen, the can we across patient controlling patients, and old managed their increased was testing patient the at place, right the think of with can more and rapidly other throughout mentioned cycle capabilities kind even something information, to make then right ecosystem can then and and use the that to those we it. the more this but host virtual idea in at in utility of is think that for of the put again, the owning partners, moving out available think and You ecosystem information increasing their bring partners the to information into important more which also patients what industries I drives information that first business, is of this really be a an helping life. forward place that time the bear, We utility the the other for

Unidentified Analyst

Thanks the questions. Great. for

Operator

Your question Savant from the of Stanley. next with Tejas line comes Morgan

line now Your open. is

Yuko Oku

Tejas. on Thanks Yuko for for taking questions. Hi, this our is

costs more about PCM, Regarding some targets how through you're balancing your of on thinking thoughts us ability your sensitivity than and to could walk perhaps competitors? the you include with

Sean George

I'm sorry.

the trade more and targets? The which was part between off first

Yuko Oku

cost? and Sensitivity

Sean George

That's right. that's right. Yes,

ctDNA time that chemistry the Archer, to helpful. side amp signature. It's our and technology has is generate equally cost cost quantitative I stack matters, for of from that our because that's though, really on good which think, where from of – now And specificity even sensitivity, number which side the to is probably go or that at kind yes, cost think the I large in that for we've a way variants, there. be extremely there's there this very the our and available just of And the business is view reimbursement. to news being controlling kind to or being the corner those important able great cell-free the a that the reimbursement most lends the a tumor is Archer very in same merged And characteristic So effective behind reason high is indications, to of most is able acquisition, itself important cost. to very

to and On going cancer people going kind clear payers very an this around would especially to with far are the little, demand developing, the reimbursement as the certainly globe. other ahead of predict battling going it's of path interesting is guidelines, that commercial broadly to I be a it's information and oncologists hand, be this ahead

the year all the that just as a important really out benefit to in become for customers. in if it we looks million as to those basis patients is battling patients markets good where is like market going get the the that's serve. these to test a And gets this monitoring of reminder price patients services. So every to longer that for cancer and indeed, XX try bigger It's we much cost because result, cancer is our live that which live good more also

we is two look next years. the as that's really So basis the in to for where cost important comes five

Yuko Oku

year this it. you. up Should to there? would year to is clarify, announce Got up, via step already into method. burn entry you in the just efforts or just later screening inorganic follow to organic assume effort this Thank And then when contemplated lead guide, cancer we cash that or from it

Sean George

our – cash R&D is solely the as comments, an this the burn something is won't effort timing No, looking and referring into to guide internal don't end or baked kind to burn, their scouting end, whatever clarify. it year. our detection up on it's we doing you're this call, guide just early past of guide I know the affect cancer evaluating external, we're if but cash

Yuko Oku

Great. Thank very you much.

Operator

comes line with of JP Peterson Tycho question from next the Morgan. Your

Casey Woodring

guys, is on Tycho. Casey Hi this

five revenues. So previously your XX% in years around double will ex-U.S. that of you've stated presence time, to

ex-U.S. How the much the what sales of impact margins? there. announced and are recently needed to Just like launches expansion wondering is CE-IVD enough LiquidPlex you force that look will gross get you FusionPlex just to and

Sean George

question. the it's walk so all Yes, an balancing – us a of that emblematic it's act it's great And actually and Ken through. Roxi

around we've Honestly, probably – could added for other it percentage to business we get solution sales that ex-U.S. to a enough have there's significantly the the that inherited and and precision said, With it marketing effort. see for distributed time. enough globe, Is oncology on we probably see. added testing global still over basis, demand Let's that us there? demand development

that to expect pay We off.

We'll the our year, also fast slowing all we other get top, carefully, of the we on middle XX managing as mentioned receive – of around But story that's on globe continue have may the and a Now, investment top it. tailwinds changes the just total the hand to Those to it this the particularly a And percent are both also U.S. are benefit the bottom. in. and we meter on, we'll of behind factor outside continue that pieces. to of And moving attention lower pricing a how outside from we're revenue different effect U.S., and but something plus that U.S. three honestly, much. something to really that and outside lot There's prices the there three is paying I invest the think yes, that's don't

Casey Woodring

the of second, see in going for this of anything are planned as of a and back or supply to what are chain? there recent the Then Got then from there, expecting year is and tuck-in of it. tracking margins sort like others you some deals to That's just helpful. inflation terms sort baked Jungla leverage gross in,

Sean George

– I'll – is short what Jungla tell you yes. answer Yes. is and answer answer I'll Diploid. on The

us – that are to basis going on overall industry out, cost fact, And reporting bus and being switch which being the signing this signing ever on for medical vanguard of improving data rate help two both costs, genetics reducing the I to claim those acquisitions year. forward. the the of of developing reduce patient next and to In would steps critical sizes the over leading out including increasing quality kind generated continues our forever of genome, we're our to sets reducing and up

the today all margin rest the Ken kind the that So cover major I points think on on two on improvement, perspective, those were very call. important of of gross the

Casey Woodring

can the Thank we that Thank be should year? in you. to And cash last of is PacBio then there for going partnership anything this paying one it. I just is this burn terms then if sneak Got how you. towards milestones partnership. in, attention generally, And much one

Sean George

Yes.

year. haven't We beginning – last we at that of the launched

a or I to to We as are five we're of financial thought, really be technically suggested, two fruits would working to there's about every that blended X,XXX genome mean, Joint more we've that. short not feasible, of that increase or these look, or about the a diagnostic for replace as a very look the at to track over close as When a undiagnosed read, Committee on PacBio point door. that it, from means today, yield them can or the with mark, we've started be disease that, the we're about it of show to really to with looks where we of It's mentioned, it in not, be three three continues the continues kids, coming kind on year looks kind in if some to in Steering lot longer getting world. in term arrangement. life. to million diseases, there's years. we things typically look last a looks be these the us talking come a have take the a that information areas, patient are the pleased diseases known important ones particularly can we timeline early That's to you objective, that And offered development get of with up milestones least these us disclosing thought long not, read are and for

about that to them continue excited going So working really try we're to accelerate and with that. to

Operator

Your next question Sykes comes from Matt Sachs. of the with Goldman line

now Your open. line is

Matt Sykes

to overall achieve Hey you've your that to pretty segment. the And at questions. and going talk the my the everybody, that this but taking you thanks smaller seen sure more you’ve growth growth drivers of we're that business significant still a growth you portion of but various in seeing. platform that for just data obviously revenue, I'm technology day, get maybe been could continue probably about help in it's could

Sean George

felt is to significant break was new early. important Albeit, it is Yes. it it And and we enough, it out.

taking. you caretakers kind so. the the first building of what are kind that or just to patient business view everybody some or feel just the on that business can view it's data point brokers we're is – to owned companies – keep important ourselves start with want it. we're whatever controlled to just major that it's different I Again, data, to because I approaches I'll feel, XXX% the do as And the and of the the doing. think however ambassadors obligated always – again, that square we so one out I This of data currently

where partners, or by on one it. patients looking control the is to trials that pharma generated Ours To-date, specific patients variants either are revenue is the histories important with therapy. for for natural or put don't

people continue a or ecosystem very of to ideas or a network activities would in in got the economic other they or and others different But there can pipeline a of data. around it's and chunk out growth and that continue ecosystem will we for on think the that's licensing. day, top being we data work that a to those future, of are whether other in will be We've we Whether that. be So grow an that business. optimistic what soon I also well ways There decision the set for models economic a for creative expand platform putting other sequencing to services, biopharma offering. using hope analytics kind some that data be patient our government partners about we're major on patient are analysis, up academic mostly to In which hope the major of that as of are future on but think of offerings based network. we that new competition pay now, years others it that this Including other that larger data end likely services. or analysis the can of of are players count tools, whatnot, then lot year or researchers, patient we

Matt Sykes

specifically Ken you maybe for bit, then conversely, seen spoke just guess capital where thinking Like that. what measured additional you reallocation about. how just more spend color Thank normalizing the spending, to it. internal are Got some of you level and of segments I business I spend sort allocation? them you on would resources given levels like increased about And of maybe a get that the of

Sean George

one. that answer can Roxi

Roxi Wen

Thank for the question. you Yes.

we're deliver to for the here the XXXX or of this year. an the balance growth, the of quarter build is is the to medicine. us, perspective, And driving, important from future to long-term then allocation and near-term and the balance allocation achieving medical us. But the because growth So change continue not here to just build top that – really we're –

management So the we Sean approach in and Sean taking near-term looking the imperatives. in – and portfolio have do a mentioned Ken – at both we're

long-term the we opportunity about take. takes the level we So long-term growth, near-term, what it's but the us really how approach strategic kind the thinking deliver the it have, to high do planning, we of immense address market

Matt Sykes

Okay. Thank you.

Operator

of line the Brennan from with comes Dan Cowen. question next Your

open. Your line is now

Dan Brennan

Hey guys.

up follow the here. for Thanks Sorry.

So weakest load stock weak, been the burn, I burn been the the burn. on towards we the the of be things the one of in would hear question often And terms guess in is the the ones. of has sector's kind your weaker dead one of

flow about we're timeline for even? M&A. at improvement break cash the that And versus to break at So you within least then for help X, what terms in the you're what XXX, XXXX the burn just with the could think I'm related of wondering assuming which in the kind of out that burn. the improvement get the seeing, would is you us Could underlying you

Sean George

appreciate no, Yes, the Dan. question,

X, one, the I XXX, inclusive would inclusive. all is say So target – the

of that's the burn, firm as note of own started genomics because in call high to that to healthcare question And executing is admittedly, that, it's decreasing I other ourselves in here, of a let's at the time. we've their point capture driving some were, opportunity. we've again, a with a a point it including choices right. been – uses mass to sooner than who obvious billion there as unique able flow in if cash going our M&A wants I is is X play earned XXX see, that all in I think past billion then be this to a to you'll we've anybody ours of target where mark, needed. terms So pushing We're that's at timing in X the We're and what is think future strategy run million, think medicine increasing the burn interesting, cash on later

plenty current sheet. comfortable capital We're I the that of of with combined we've do around. we balance actually enough a plan something and debt, of since kind And there burn we in our very reduce traditional raise is the the time markets. than comes ability before doing support to open more you got think we and time the plenty about out you mentioned think thereafter as about be look our XX with to won't that need,

the So I'd say kind opportunity growth good our front couple feel pretty about comfortably of years. sit with we're our balance current plan actually and and of sheet in with the us, sitting next

in don't given On front a the time, reason put story. a – the the really time in we of the us, growth again, it's opportunity

time flip cash translate what we get and I then we'll out. certainly revenue, in by to there. how the you just top between get way now on quickly billion And so time think top line flow we over And as the be matter see, line then it between plays $X we'll of then, again, to a operating the to And and now growth, the depending we'll to expenses we that's meter positive.

Dan Brennan

in big of think you in thinking part on thank need, sense the then an might see on an do been needs, of of any plan you to we I go? one your mean, one, quite obviously what your should how you XXXX, M&A in terms about just how you've areas pipeline look be it's XXXX just and strategy, that And it, your in filling growth in deal a you. material from important maybe strategy how final active Got and Sean, M&A,

Sean George

is Yes, that the I of mean, the market kind thing most, the conditions has M&A changed considering plan.

going whereas content cost our interesting. serious to company, guide of still So, said, quickly stick there's out said, anything very think assets, reduce pipelines, the the I We're burn, really that a top, bottom. operations of digital have table kind basically digitize increase off that With and of plenty technologies, that. there basis I is technology now. considered we're about the to really would We're might can capabilities all like interesting of, middle that for our the we for the internal that's that

can, about purchase. Some have of or that could that even you kind asked profit recently revenue we gross

say maybe Now change table, the in would I never time I on But encompassed I we've would year the to I M&A think believe of But in done, uncertainty the something that that's really like those past that, I We the said, those on could the another in don't margin. that's call so. it's given approach would so be the say. forecast. kind the all in that's – make given are burn just market, but the something given changes wise next or I

Dan Brennan

Great. Thanks, Sean.

Operator

concludes attending. There conference are you at no time. further This Thank this questions for today's call.

may disconnect. now You

Invitae (NVTAQ) 25 Feb 222021 Q4 Earnings call transcript